Orthofix Medical Inc.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ORTHOFIX MEDICAL INC. | ||
| Dated: February 24, 2026 | By: | /s/ MASSIMO CALAFIORE |
|---|---|---|
| Name: | Massimo Calafiore | |
| Title: | President and Chief Executive Officer, Director | |
| Dated: February 24, 2026 | By: | /s/ JULIE ANDREWS |
| Name: | Julie Andrews | |
| Title: | Chief Financial Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ MASSIMO CALAFIOREMassimo Calafiore | President and Chief Executive Officer, Director(Principal Executive Officer) | February 24, 2026 |
| /s/ JULIE ANDREWS Julie Andrews | Chief Financial Officer(Principal Financial and Accounting Officer) | February 24, 2026 |
| /s/ MICHAEL FINEGANMichael Finegan | Director, Chair of the Board | February 24, 2026 |
| /s/ ALAN BAZAARAlan Bazaar | Director | February 24, 2026 |
| /s/ WAYNE BURRISWayne Burris | Director | February 24, 2026 |
| /s/ VICKIE CAPPSVickie Capps | Director | February 24, 2026 |
| /s/ JASON HANNONJason Hannon | Director | February 24, 2026 |
| /s/ JOHN HENNEMAN, IIIJohn Henneman, III | Director | February 24, 2026 |
| /s/ CHARLES KUMMETHCharles Kummeth | Director | February 24, 2026 |
| /s/ SHWETA MANIARShweta Maniar | Director | February 24, 2026 |
| /s/ MICHAEL PAOLUCCIMichael Paolucci | Director | February 24, 2026 |
Statement of Management’s Responsibility for Financial Statements
To the Shareholders of Orthofix Medical Inc.:
Management is responsible for the preparation of the consolidated financial statements and related information that are presented in this Annual Report. The consolidated financial statements, which include amounts based on management’s estimates and judgments, have been prepared in conformity with accounting principles generally accepted in the United States. Other financial information in the report to shareholders is consistent with that in the consolidated financial statements.
The Company maintains accounting and internal control systems to provide reasonable assurance at a reasonable cost that assets are safeguarded against loss from unauthorized use or disposition, and that the financial records are reliable for preparing financial statements and maintaining accountability for assets. These systems are augmented by written policies, an organizational structure providing division of responsibilities, and careful selection and training of qualified personnel.
The Company engaged Ernst & Young LLP, independent registered public accountants, to audit and render an opinion on the consolidated financial statements in accordance with auditing standards of the Public Company Accounting Oversight Board (United States). These standards include an assessment of the systems of internal controls and tests of transactions to the extent considered necessary by them to support their opinion.
The Board of Directors, through its Audit and Finance Committee, consisting solely of outside directors of the Company, meets periodically with management and our independent registered public accountants to ensure that each is meeting its responsibilities and to discuss matters concerning internal controls and financial reporting. Ernst & Young LLP has full and free access to the Audit and Finance Committee.
Wayne Burris
Chairman of the Audit and Finance Committee
Massimo Calafiore
President and Chief Executive Officer, Director
Julie Andrews
Chief Financial Officer
Index to Consolidated Financial Statements
| Page | ||
| Index to Consolidated Financial Statements | F-1 | |
|---|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | F-2 | |
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | F-4 | |
| Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2025, 2024, and 2023 | F-5 | |
| Consolidated Statements of Changes in Shareholders’ Equity for the years ended December 31, 2025, 2024, and 2023 | F-6 | |
| Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024, and 2023 | F-7 | |
| Notes to the Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.